I know a sale when i see one :-) Keep the faith TLD1433
TLD1433 (also known as Ruvidar
® and “Theralase
®) was the first Ru(II)-based photosensitizer to enter clinical trials and successfully complete a phase 1b human clinical trial (NCT03053635). A phase 2 study is ongoing (NCT03945162) [
114,
115] to evaluate TLD1433 in non-muscle-invasive bladder cancer patients. It has been recently suggested as a repositioning drug for the treatment of conjunctival melanoma, which is a rare but often deadly ocular cancer [
116], and human lung adenocarcinoma [
117]. Recently, Karges (2022) [
118] reviewed the clinical development of TLD1433 and other metal-containing compounds, including rostaporfin (Purlytin
®), motexafin lutetium (Lutrin
®/Antrin
®), and the sulfonated aluminium phthalocyanin (Photosens
®), bearing the different metals Sn, Lu, and Al, respectively, as well as padeliporfin (WST09) and padeliporfin (WST11 or TOOKAD
® soluble), which contain Pd, as photosensitizers for the photodynamic therapy of cancer.
Pharmaceuticals | Free Full-Text | Complexes of Ruthenium(II) as Promising Dual-Active Agents against Cancer and Viral Infections (mdpi.com)